Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 6/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9097795 | 0.86 | CA1 (0.55) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL10908046 | 0.85 | CA1 (0.53) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL10666079 | 0.85 | CA1 (0.53) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL9732748 | 0.80 | CA1 (0.57) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL757927 | 0.80 | CA1 (0.57) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL14519933 | 0.79 | PRKD3 (0.58) | MEN1KMT2AHTR1A | |
| SCHEMBL9041969 | 0.78 | CA1 (0.46) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL34472504 | 0.77 | CA1 (0.53) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL27403973 | 0.77 | CA1 (0.58) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL511923 | 0.77 | CA1 (0.63) | CA1CA2CA9F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | disclosed |
| US-20150093692-A1 | PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM USED THEREFOR, AND ELECTRONIC DEVICE MANUFACTURING METHOD AND ELECTRONIC DEVICE USING THE SAMEDEVICE MANUFACTURING METHOD AND ELECTRONIC DEVICE USING THE SAME | FUJIFILM CORPORATION (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | CA1 3328/4885CA2 3798/4885CA9 3551/4885 |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | TPX2, AIMP2, CDYL2 | CA1 3749/4885CA2 1511/4885CA9 1248/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | CA1 2629/4885CA2 1149/4885CA9 828/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CA1 3353/4885CA2 3978/4885CA9 4566/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | CA1 4161/4885CA2 4458/4885CA9 3577/4885 |
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, PREP | CA1 2001/4885CA2 2383/4885CA9 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.